logo

PVLA

Palvella·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

PVLA fundamentals

Palvella (PVLA) released its earnings on Nov 10, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -1.03 (YoY +52.97%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-1.03
+52.97%
Report date
Nov 10, 2025
PVLA Earnings Call Summary for Q3,2025
  • Pipeline Expansion: Qtorin Rapamycin advancing in 3 Phase II/III studies; Qtorin Pitavastatin entering clinic for DSAP.
  • Financial Strength: $63.6M cash runway through Q2 2027; disciplined cost control supporting rare disease focus.
  • Regulatory Strategy: sNDA pathway to expand indications post-MLM approval; Phase III SELVA study on track for Q1 2026 readout.
  • Commercial Readiness: Dual-source manufacturing partners; stability data ensures seamless transition to commercial supply.
EPS
Revenue

Revenue & Expenses

Key Indicators

Palvella (PVLA) key financial stats and ratios, covering profitability, financial health, and leverage.
Palvella (PVLA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Palvella (PVLA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Palvella (PVLA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Palvella (PVLA) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Palvella (PVLA) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield